Home › Research › Prevention and risk
Herpes zoster vaccination and incident dementia in Canada: an analysis of natural experiments
Pomirchy M, Chung S, Bommer C, Strobel S, Geldsetzer P. The Lancet Neurology, 2026
Topic: Risk, prevention and care in population studies
Plain-language summary
We aimed to determine the effect of live attenuated herpes zoster vaccination on incident dementia diagnoses among people aged 70 years and older using a natural experiment in Ontario, Canada, and to triangulate these findings, using a second natural experiment in Ontario and a quasi-experimental approach that uses data from multiple Canadian provinces. We compared patients born immediately before versus immediately after Jan 1, 1946, in our primary analysis, and immediately before versus immediately after Jan 1, 1945, in our secondary analysis, as these thresholds determined eligibility for herpes zoster vaccination in Ontario. Additionally, we used synthetic difference-in-differences and a synthetic control method to compare trends in dementia incidence (before versus after the start date of the herpes zoster vaccination programme) among birth cohorts in Ontario who were eligible for vaccination with the same birth cohorts (all of whom were ineligible for vaccination) in other provinces of Canada.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 232,124 participants. This Canadian study used natural experiments to test whether live attenuated herpes zoster vaccination affects new dementia diagnoses in people aged 70 and older. Reported effect size: -2.0 percentage points (95% CI -3.5 to -0.4) absolute reduction in new dementia diagnoses over 5.5 years.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Pomirchy, M., Chung, S., Bommer, C., Strobel, S., & Geldsetzer, P. (2026). Herpes zoster vaccination and incident dementia in Canada: an analysis of natural experiments. The Lancet Neurology. https://doi.org/10.1016/S1474-4422(25)00455-7
Vancouver
Pomirchy M, Chung S, Bommer C, Strobel S, Geldsetzer P. Herpes zoster vaccination and incident dementia in Canada: an analysis of natural experiments. The Lancet Neurology. 2026. doi:10.1016/S1474-4422(25)00455-7. PMID: 41579903.
BibTeX
@article{pomirchy2026-41579903,
author = {Pomirchy, M. and Chung, S. and Bommer, C. and Strobel, S. and Geldsetzer, P.},
title = {{Herpes zoster vaccination and incident dementia in Canada: an analysis of natural experiments}},
journal = {The Lancet Neurology},
year = {2026},
doi = {10.1016/S1474-4422(25)00455-7},
pmid = {41579903},
url = {https://doi.org/10.1016/S1474-4422(25)00455-7}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- We aimed to determine the effect of live attenuated herpes zoster vaccination on incident dementia diagnoses among people aged 70 years and older using a natural experiment in Ontario, Canada, and to triangulate these findings, using a second natural experiment in Ontario and a quasi-experimental approach that uses data from multiple Canadian provinces.
- We compared patients born immediately before versus immediately after Jan 1, 1946, in our primary analysis, and immediately before versus immediately after Jan 1, 1945, in our secondary analysis, as these thresholds determined eligibility for herpes zoster vaccination in Ontario.
- Additionally, we used synthetic difference-in-differences and a synthetic control method to compare trends in dementia incidence (before versus after the start date of the herpes zoster vaccination programme) among birth cohorts in Ontario who were eligible for vaccination with the same birth cohorts (all of whom were ineligible for vaccination) in other provinces of Canada.
Why it matters
This Canadian study used natural experiments to test whether live attenuated herpes zoster vaccination affects new dementia diagnoses in people aged 70 and older. The text provided describes the methods but does not report the results, so no conclusion about the vaccine's effect can be drawn.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Study designcohort
- Participants232,124
- Effect size-2.0 percentage points (95% CI -3.5 to -0.4) absolute reduction in new dementia diagnoses over 5.5 years
- Evidence strengthModerate
Limitations
Primary care records only; effect of eligibility rather than vaccination; live attenuated vaccine; 5.5-year follow-up; mechanism still unexplained.
How this study scored 72/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on senior author's track record and free to read, so those were left out: it earned 68 of the 94 points we could judge it on, which is 72 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (The Lancet Neurology) |
| Journal's citation record | 3 / 4 | The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 4 / 4 | 232,124 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 18 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 9.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 6 / 6 | Cited 80.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 2 / 4 | Cited 18 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author P. Geldsetzer holds only 3 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 3 / 3 | Stanford University: institution h-index 2,684 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41579903) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 68 / 94 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 68 of the 94 points we could judge it on is 72 out of 100. |
| Total | 72 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/S1474-4422(25)00455-7
- PubMed: 41579903
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
In the news
1 news article on alzhub's news page cites this paper.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Prevention and risk from nearby years
Also tagged “prevalence”
1,223 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,223 tagged studies.